key: cord-0976641-jyx1j3wy
authors: Asfour, Hani Z.; Alhakamy, Nabil A.; Eljaaly, Khalid; Aloafi, Ahmed L.; Tantawy, Mohamed A.; Hussein, Khulood S.; Aldarmahi, Ahmed A.; Elfaky, Mahmoud A.
title: Molecular Docking Studies of HIV TAT and sitagliptin nano-formula as potential therapeutic targeting SARS-CoV2 protease
date: 2021-08-08
journal: Journal of the Indian Chemical Society
DOI: 10.1016/j.jics.2021.100119
sha: 0eee61a6cbf720dbb80dd9f1fa6eea1e8002444e
doc_id: 976641
cord_uid: jyx1j3wy

The outbreak of COVID-19 pandemic regarded as a major health/economic hazard. The importance of coming up with mechanisms for preventing or treating SARS-CoV-2infection has been felt across the world. This work aimed at examining the efficiency of Sitagliptin (SIT) and human immunodeficiency virus type 1 (HIV-1) trans-activator transcription peptide (TAT) against SARS-CoV-2 virus. 3CL-protease inhibition activity and docking studies were examined. According to the results, the prepared complex’s formula was as follows 1: 1 SIT: TAT molar ratio, whereas zeta potential and particle size values were at 34.17 mV and 97.19 nm, respectively. This combination did exhibit its antiviral potentiality against SARS-CoV-2 via IC50 values of 9.083 5.415, and 16.14 μM for TAT, SIT-TAT, and SIT, respectively. In addition, the complex SIT-TAT showed a significant (P < 0.001) viral-3CL-protease inhibitory effect. This was further confirmed via in silico study. Molecular docking investigation has shown promising binding affinity of the formula components towards SARS-CoV-2 main protease (3-CL).

The dipeptidyl peptidase-4 (DPP4) is expressed in many tissues and cell types, including kidney, intestine, liver, thymocytes, and several cells of hematopoietic lineage [1] . DPP4 is not a possible receptor for SARS-COV-2 entry [2] . However, the prolonged and excessive cytokine responses that are noted in COVID-19 patients can be decreased J o u r n a l P r e -p r o o f by Sitagliptin (SIT) [3] [4] [5] . SIT is anti-diabetic drug used to decrease incertins, which by its turn increase insulin re-lease leading to decreasing blood sugar [6] . A possible immunomodulatory effect of SIT was seen in the plasma C-Reactive Protein (CRP) and procalcitonin reduction process [7] [8] [9] . Type 2 diabetic patients who have been diagnosed with COVID-19 are recently said to have developed even bad outcomes due to poor glucose control in their bodies [7, 10] . Humoral and cellular immunity alterations which are age dependent can lead to a rise in the viral replication and a longer suffering from inflammation which could be indirectly the reason for poor death outcomes and some of these changes can be managed by the Dipeptidyl-peptidase 4 (DPP4) Inhibitors like SIT [11] [12] [13] . An intriguing fact is that these inhibitors up-regulate the soluble DPP4 plasma levels, but this is separated from the inflammation and it's extent, and can also be one more mechanism by which the SIT could have optimal effects [7, 14] . The researchers used an integrative bioinformatics method that began with a search of the biomedical literature for high-confidence SIT-protein/gene connections, then moved on to functional analysis utilising network analysis and pathway enrichment. As a result of the findings, we propose SIT as a putative target for COVID-19 treatment since the identified DPP4 networks are substantially enriched in viral activities essential for viral entrance and infection.

Being combined with cell-penetrating peptides (CPPs), the efficiency and cellular uptake of the anti-COVID-19 medicines can be improved [15] [16] [17] [18] . CPPs have less than J o u r n a l P r e -p r o o f 30 amino acid residues [19, 20] . They are capable of crossing cell membranes by emitting minimal toxicity through energy dependent/independent mechanisms, and even not needing any specific chiral recognition [21] . CPPs being merged with drug molecules has been the main anti-viral technique for CPPs and a few CPPs have gone to the extent of demonstrating anti-viral features [17, 22, 23] . The human immunodeficiency virus type 1 (HIV-1) has the ability to penetrate cells. The Trans-Activator Transcription peptide (TAT) of of HIV1 has set off a whole generation of intra-cellular delivery of loaded therapeutics [24] [25] [26] [27] [28] [29] [30] . The TAT peptide which is rich with positively charged amino acids is utilized as a research tool to improve the transport and delivery of the drugs, DNA, proteins, RNA, nanoparticles and viruses in the cytoplasm [24] [25] [26] [27] [28] [29] [30] [31] . These anti-COVID-19 drugs' efficacy can be enhanced by associating it with TAT peptide [32] . Evaluating the efficiency and effectiveness of the combination of TAT and SIT against SARS-CoV-2 was the objective of this research, to help open the doors to the research that could help eliminate this pandemic virus. As of now, no medication or vaccine has been successful to treat and cure COVID-19 patients [33] . Hence, this repurposed drug could be an excellent substitute with the ability to fight and possibly defeat this virus.

The aim of this work was to evaluate and the efficiency and effectiveness of the TAT and SIT optimized complex against isolate of SARS-CoV-2. before being whirled for a couple of minutes before its dissolution. A 1 millilitre aliquot of mixed solutions was diluted in 10 millilitres of the same buffer to determine the Zeta potential and the size of particles.

The prepared SIT-TAT formations' nano-particles had been spread throughout the waterbody and measured a particle-size analyser (Zetatrac; Microtrac Inc., Montgomeryville, PA, USA), used to analyze the size of particles and the Zeta potential. Three readings were done to determine the average Zeta potential and size of particles. 

Another analysis called the FTIR analysis was performed to view the interaction taking place between TAT and SIT spectrums, which was estimated at 4000-400 cm−1 With the help of the FTIR spectrophotometer (Nicolet IZ 10, Thermo Fisher Scientific, Waltham, MA, USA).

A fluorescent substrate that harbored the cleavage site of SARSCoV-2 Mpro, SARS-CoV-2 3CL Protease, GenBank Accession No. YP_009725301, a.a. 1-306, denoted in an expression system of E. coli, MW 77.5 kDa., as well as buffer comprising 100 mM NaCl, 20 mM Tris, pH 7.3, and 1 mM EDTA, 1 mM DTT utilized for inhibition assay, MW 507.5 Da was leveraged as control and GC376 a 3CL protease inhibitor. In the cleavage assay based on FRET, the Edans' fluorescence signal formed via a Flx800 fluorescence spectrophotometer owing to the substrate's cleavage by 3CL Protease was observed at an emission wavelength of 460 nm where excitation was 360 nm [34] . To begin with, 30 J o u r n a l P r e -p r o o f µL of diluted SARS-CoV-2 3CL Protease was inserted into a 96-well plate that contained test formula's pre-pipetted 10 µL. This was followed by the incubation of the combination at room temperature for 30 minutes via slow shaking. The reaction was then started by adding 10 µL of substrate dissolved inside the buffer at volume of 50 µL final volume, before being incubated at room temperature for four hours. After sealing the plates, the measurement of fluorescence intensity was checked in a microtiter plate-reading fluorimeter with a 360 nm wavelength that could detect emissions at 460 nm wavelength [35, 36] .

The investigation of molecular docking was carried out via the Molecular Operating Environment (MOE) platform. The MOE builder module was used to build the two studied ligands that then underwent energy-minimization through MMFF-mediated partial charges and the gradient used was 1x10 -3 Kcal/Å [37] . These minimized and prepared ligands were subsequently saved in the format of chemical file (Molecular Data Base) so that it could be used in line with the protocol of molecular docking. The biological target was obtained from RCSB-Protein Data Bank (PDB ID: 6LU7) before being prepared within the MOE protein preparation tool, where 3D-protonation and auto-correction for atoms types, connections, and charges were adopted. Thereafter, the binding site was defined by MOE Alpha Site Finder, after which the active site was J o u r n a l P r e -p r o o f refined to involve the crucial binding residues reported within current literature.

Dummy atoms generated from the obtained alpha spheres were assigned as polarhydrophobic descriptors of the pre-defined M pro active site. The MOE rigid docking protocol was adopted based on former analysis of M pro binding site. The flexibility of Mpro-substrate binding pocket was as both S1' as well as S1 subsites were either too rigid or underwent minor changes at the end [38] . A high correlation of superposition between M-pro's apo-and holo-states of 6M03 and 6LU7, respectively denoted a nonpresentable discrepancy between the two states [39, 40] . Thus, a non-relevant impact of the local ligand induced-fit effect to M pro binary complex structure within the macromolecule crystalline states. Taking cues from the nee docking algorism, the development of ligand conformations was undertaken via bond rotation, inside the active site in congruence with the triangle matcher approach, before being ranked using the London dG scoring function. The retained number of poses (preset for 10 poses) were then refined by minimizing energy in the pocket before being rescored with GBVI/WSA dG forcefield-based scoring function depending on Coulombic electrostatic using the currently loaded charges, protein-ligand van der Waals score, solvation electrostatic, and exposure-weighed surface area weighted [41, 42] . The rootmean-square deviation (RMSD) values were considered to assess the validity of the docking protocol keeping the cut-off below 2.0 Å and 3.0 Å for SIT and the proteinomimetic ligand, HIV-1 TAT protein, respectively. PyMol graphical interface J o u r n a l P r e -p r o o f software was used to analyze and visual investigate the interactions involving ligandprotein binding [43] .

This was done using the IBM SPSS® statistical software (Version 25) procured from Chicago, IL-based SPSS Inc. Both ANOVA as well as Tukey's post were implemented in case multiple comparisons were made. Sets of experiments were reported using Standard Deviation. These experiments were then conducted a minimum of four times prior to examining the results. p values exceeding 0.5 were deemed significant.

SIT-TAT nano-formulations were developed according to a full three-factor bi-level (2 3 ) factorial design to obtain the optimized formula. The explored independent variables were SIT concentration (mM, X1), TAT concentration (mM, X2), and pH (X3), while the measured responses were particle size (PS, nm, Y1) and zeta potential (ZP, mV, Y2).

The antiviral activity through testing its inhibition effect on 3-CL main protease.

Finally, Molecular docking studies were carried out to interpret the observed enzyme inhibition activities based on drug-protein interactions.

J o u r n a l P r e -p r o o f

Transmission electron microscope (TEM) photographs of optimized SIT-TAT complex showed rounded structures revealing some aggregations potentially caused by the drying process during sample preparation ( Figure 1I ).

Fourier-Transformed Infrared (FTIR) investigation as carried out to the interaction taking place between TAT and SIT spectrums, which was estimated at 4000-400 cm−1. 

Due to the 3CLpro essential role in all coronaviruses for its replication, 

To derive more insights into obtained in vitro SARS-CoV-2 main proteases (Mpro) inhibition activity, molecular docking studies were conducted to investigate the predicted ligand-protein binding interactions for SIT along with formulation components. The SARS-CoV-2 Mpro binary complex with the irreversible Michaelacceptor peptidomimetic inhibitor, N3 (PDB ID: PRD_002214) was the adopted atomic crystallized structure for the presented in-silico studies. The crystallized ligand covalently fits within the substrate active site resembling the Mpro natural substrate, which can then prevent further catalysis. Typically, the Mpro binding cavity consists of four crucial clefts or subsites, S1'-S4, corresponding to the P1'-P4 peptide partitions of the natural substrate amino acids ( Figure 3A ) [43] .

Throughout the presented molecular docking studies, SIT presented relevant accommodation of the target binding site with a significant docking score of (S = -5.739

Kcal/mol; RMSD = 1.363 Å). The fused triazolo [4, 3-a] pyrazine ring of the ligand was settled at the S1 subsite and forecasted polar contacts were Gly143 and Ser144 ( Figure   3B ). The ring exhibited a close proximity with Cys145, a S1' catalytic dyad, without predicted polar interactions. However, the SIT 3-trifluoromethyl substituent exhibited preferential anchoring at polar side of S1 pocket comprising the hydrophilic residues, His163, Glu166, and His172. Another hydrogen binding was suggested between the carbonyl of SIT aliphatic linker and important residue Gln189 that can further stabilize the ligand at S3 subsite. Finally, the hydrophobic phenyl group at the terminal part of J o u r n a l P r e -p r o o f SIT was forecasted to be deeply anchored towards the S1' subsite where a face-to-face sandwiched π-π stacking was depicted with the catalytic His41 amino acid. An overlay of SIT binding pose, with the crystallized ligand N3, showed relevant binding poses regarding the ligand's terminal phenyl and fused triazolo[4,3-a]pyrazine scaffolds. The trisubstituted phenyl group depict significant orientation that is comparable to the N3's leucine residue. Meanwhile, the fused triazolo [4, 3-a] pyrazine scaffold predicted comparable orientation at the S1 polar side similar to the pyrrole residue of N.

In terms of the formulation component, TAT exhibited significant accommodation of the binding cavity with a quite higher average docking score (S = -6.722 Kcal/mol; RMSD = 2.731 Å) than that of SIT. Due to its greater size, this undecapeptidomimetic ligand presented relevant anchoring within all pocket subsites of the Mpro substrate binding pocket and adjacent surface clefts ( Figure 3C ). Additionally, stabilization of the TAT-protein complex was forecasted via various polar interactions with significant residues. The Glu166 S1 residue contributed in a hydrogen bonding pair with the Nterminal of TAT protein. Double polar interactions were observed between the mainchains of tyrosine-glycine, at the TAT N-terminal, and Glu166 sidechain at S1 pocket subsite. Additionally, both Phe140 and Leu141 showed close proximity to the TAT tyrosine residue, suggesting pertinent hydrophobic interactions for TAT-S1 subsite affinity. In terms of TAT anchoring toward the Mpro S3 subsite, Gln189 illustrated a significant polar contact with the ligand's lysine residue. It is notable that a double J o u r n a l P r e -p r o o f polar interaction with Thr25 sidechain was also exhibited to confirm the reported role of Thr25 for fixing Mpro inhibitors in close proximity to the S1' subsite. An overlay of N3 and TAT conformation depicted minimal superimposition as far as both ligands' Calpha backbone is concerned, due to the more extended structure of HIV-1 TAT protein.

However, the TAT N-terminal arginine residue exhibited great superposed conformation with the proline residue of N3 inhibitor at the S1 subsite. In a similar vein, both the N-terminal arginine of TAT and N3's modified residue (thiazole sidechain) predicted comparable orientation in close proximity to the S3 subpocket.

A comparison of the conformation of both SIT and HIV-1 TAT protein within the target binding site has revealed interesting findings. Despite the fact that both ligands predicted significant accommodation of the Mpro active site, their relative orientations and binding interfaces within the target pocket can be seen to be quite different ( Figure   3D ). Owing to its smaller size, SIT suggested deeper anchoring within the target subsites as compared to the undecapeptidomimetic ligand, HIV-1 TAT. SIT showed greater buried binding mode where residues of both S1 and S3 highly shield the small ligand molecule from being highly solvent exposed. Separately, the forecasted pose of TAT protein is more confined within the target pocket-solvent interface. target is shown in surface 3D-representation with its active site being colored in orange, green, blue, and red, in respective to its subsite pockets (S1', S1, S2, and S3, respectively). 

Another important target is the 3CL protease, as it prevents the replication of the SARS-CoV-2, specifically when it hasn't been located in host cells [44] . binding [38, 42, [45] [46] [47] . Generally, interaction with the Mpro catalytic dyad, (His41 and Cys145) within S1' subsite represent great contribution to strong ligand-protein binding and catalysis inhibition [38] . Additionally, the sidechains of Met165 and

Gln189 from S3-subsite as well as His41, Met49, and Asp187 within S2-subsite can provide valuable non-polar interactions serving as the hydrophobic grip pinning J o u r n a l P r e -p r o o f ligands to the binding site [38] . Moreover, ligand anchoring at Mpro site can be achieved via hydrophilic interactions with Glu166 mainchain at S1 subsite. Other several relevant residues recognized via different authors are Thr24, Thr25, Pro168, His172, Phe185, and Ala191 [46, 48, 49] .

Within the presented study, both SIT and TAT showed preferential accommodation of the Mpro pockets. Residue-wise interaction with both ligands showed significant polar interaction with Glu166 being responsible for anchoring of many of the reported ligands and introduced as one of the indispensable S1subpocket residues. The latter confirms the significance of Glu166 binding for fixing both small molecules and proteinomimetic ligands within the Mpro binding site.

Only SIT managed to depict relevant contacts with Mpro catalytic dyad which was reasoned for its deep site anchoring owing to its small size. Despite the lack of relevant polar interaction with catalytic dyad, SIT managed to predict significant hydrophobic contact with His41. Such ligand pose suggested a hampering role of SIT small ligands towards the Mpro catalytic machinery being previously introduced by Gimeno and research group [38] . The in-silico study further depicted pocket accommodation of both ligands within Mpro through several polar and hydrophobic contacts with important sub-pocket residues. Significant contacts with S1' Thr25, S1 Phe140, Leu141, Gly143 and Ser144, and/or S3 Gln189 suggested the role of these residues for stabilizing SIT/TAT within the Mpro active site. The latter J o u r n a l P r e -p r o o f depicted ligand/pocket residue interaction came in great agreement with several reported studies confirming the significant binding of SIT and TAT at the Mpro pocket [38, 42, [45] [46] [47] .

The most interesting in-silico finding introduced within this study, is the ability of both investigated ligands to simultaneously accommodate the Mpro pocket. The deep pocket anchoring of SIT was suggested owing to the ligand's small molecular size as well as its preferential interactions with deep pocket lining residues. On the other hand, the confinement of TAT to the target pocket-solvent interface side was more related to the ligand's extended conformation. However, the extensive polar network and relevant hydrophobic contacts between the TAT protein and relevant pocket residues, of reported role in ligand entrance and binding, can provide evidence for the great stability of TAT at the Mpro active site. Based on the above findings, it is suggested that both SIT and TAT protein can concurrently bind to the SARS-CoV-2 Mpro pocket within a predicted binding mode being highly stabilized.

Moreover, the latter computational behavior of combined formulation of SIT and TAT at the target active site could provide an explanation of the depicted synergistic biological activity of SIT/TAT formulation as compared to sole drug.

J o u r n a l P r e -p r o o f

The SIT-TAT complex showed a promising antiviral activity against isolate of SARS-CoV-2 over its component. In addition to, we explore the mechanism of this activity through testing its inhibition effect on 3-CL main protease. 

Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV

A Novel Purification Procedure for Active Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2 Molecules

Landscape Profiling Analysis of DPP4 in Malignancies: Therapeutic Implication for Tumor Patients With Coronavirus Disease

Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19

Is sitagliptin effective for the treatment of COVID-19?

Incretins: Their physiology and application in the treatment of diabetes mellitus

Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin Med

Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and covid-19: A multicenter case-control retrospective observational study Diabetes Care

Sitagliptin: A potential drug for the treatment of COVID-19?

COVID-19 and diabetes mellitus: from pathophysiology to clinical management

Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?

Age-related differences in humoral and cellular immune responses after primary immunisation: Indications for stratified vaccination schedules

Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes

DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?

Cell-Surface Interactions on Arginine-Rich Cell-Penetrating Peptides Allow for Multiplex Modes of Internalization Acc

Interaction of nanoparticles and cellpenetrating peptides with skin for transdermal drug delivery

Combination of cell-penetrating peptides with nanoparticles for therapeutic application: A review Biomolecules 9

Arginine-rich cell-penetrating peptides induce membrane multilamellarity and subsequently enter via formation of a fusion pore

Cell-penetrating peptides for drug delivery across membrane barriers

Mechanism Matters: A Taxonomy of Cell Penetrating Peptides Trends

Cell-penetrating peptides for antiviral drug development Pharmaceuticals

The antimicrobial and antiviral applications of cell-penetrating peptides Cell-Penetrating Peptides

Preparation and evaluation of lidocaine hydrochloride-loaded TAT-conjugated polymeric liposomes for transdermal delivery Int

Conjugates of Antisense Oligonucleotides with the Tat and Peptides : Effects on Cellular Uptake

Vitamin E TPGS based transferosomes augmented TAT as a promising delivery system for improved transdermal delivery of raloxifene

TAT-liposomes: a novel intracellular drug carrier

Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models

Optimized Conjugation of Fluvastatin to HIV-1 TAT Displays Enhanced Pro-Apoptotic Activity in HepG2 Cells

Progress in Research and Application of HIV-1 TAT-Derived Cell-Penetrating Peptide

Lipid-based nano delivery of Tat-peptide conjugated drug or vaccine-promising therapeutic strategy for SARS

Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action

Peptide aldehyde inhibitors challenge the substrate specificity of the SARScoronavirus main protease

Tomatidine inhibits porcine epidemic diarrhea virus replication by targeting 3CL protease

Tea Polyphenols EGCG and Theaflavin Inhibit the Activity of SARS-CoV-2 3CL-Protease in Vitro Evidence-based Complement

The anticancer activity for the bumetanidebased analogs via targeting the tumor-associated membrane-bound human carbonic anhydrase

Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition Int

Identification of novel CDK2 inhibitors by a multistage virtual screening method based on SVM, pharmacophore and docking model

Protective Activities of some Extracts from Euphorbia retusa Leaves towards CCl 4-Induced liver injuries in Rats Chem

Targeting SARS-CoV-2 Nsp12/Nsp8 interaction interface with approved and investigational drugs: an in silico structure-based approach Taylor Fr

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors Nature

AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2 bioRxiv

Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors

Molecular docking reveals the potential ofSalvadora persicaflavonoids to inhibit COVID-19 virus main protease RSC Adv

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors Science (80-. )

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: Virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates

A 2020 Discovery of M protease inhibitors encoded by SARS-CoV-2 Antimicrob. Agents Chemother